Becton, Dickinson and Company

BDX · NYSE · USD

Can New BD turn leadership in mature hospital consumables into durable mid-single-digit growth once the Alaris comparison, vaccines and China stop dragging on reported sales?

Last 4 earnings calls · through Q3 FY2026

Bull case

  • Scaling growth platforms

    BD's fastest businesses, biologics delivery, patient monitoring, PureWick and tissue regeneration, are growing faster than the rest and now set the company's growth rate.

  • Earnings guidance raised

    Management has lifted its full-year earnings guidance as the year progressed, which supports the view that extra commercial spending is converting into sales.

  • Internal improvement system

    BD Excellence, the company's own productivity system, keeps lowering plant costs and funds both price competition and reinvestment in selling and research.

  • Recurring hospital consumables

    Leadership in most of its markets and a revenue base that is almost all consumables give BD a recurring position that hospitals replace slowly once installed.

Bear case

  • Alaris comparison unwinds

    The Alaris pump replacement cycle that ran ahead of schedule is reversing, so the comparison alone subtracts from reported growth well into the next fiscal year.

  • China and vaccine demand

    China procurement price cuts and weaker vaccine ordering sit outside management's control and have repeatedly pulled reported growth below the underlying business.

  • Tariffs and cash returns

    Tariffs take most of the margin gain, and BD returns more cash to shareholders than it generates while net debt stays above its stated target.

  • Narrow base of growth

    Growth now rests on a few platforms and on pharmaceutical customers whose decisions about GLP-1 volumes and vaccine orders BD does not control.

Bull and bear points

Growth & Execution

In short: Four platforms are growing at double digits, while Alaris and China still pull the reported growth rate down.

Bull · 2

  • Four platforms are growing at double digits

    Biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration are outgrowing the rest of the portfolio, so the company's growth rate increasingly depends on them rather than on mature consumables.

    Q3 FY2026 call

  • Full-year earnings guidance raised

    In February management guided fiscal 2026 adjusted EPS to $12.35 to $12.65; by August the range was raised to $12.62 to $12.72, with revenue now expected at the high end of the low single-digit range.

    Tone shiftQ1 FY2026 → Q3 FY2026
Bear · 2

  • Alaris becomes a larger drag next year

    The pump replacement cycle that ran ahead of schedule peaked last year; management guides the comparison to subtract about 200 basis points from fiscal 2027 revenue growth before it clears in fiscal 2028.

    Q2 FY2026 call

  • China procurement keeps cutting prices

    Volume-based procurement is expected to cover about 80% of BD's China portfolio by the end of fiscal 2026, and management guides the region to a mid-teens decline with no recovery built into the plan.

    Q4 FY2025 call

Profitability & Financial Strength

In short: Productivity gains and rising cash flow are offset by tariffs and by payouts above free cash flow.

Bull · 2

  • BD Excellence funds margins despite tariffs

    The internal improvement system delivered about 8% gross productivity in the plants this quarter, which is what lets BD hold operating margin near 25% while absorbing tariff costs and paying for extra sales staff.

    Q3 FY2026 call

  • Cash conversion now has a stated target

    A year ago management would only say free cash flow conversion would improve significantly; it now points to a 90% conversion target, which sets a measurable standard for how much cash the business should produce.

    Tone shiftQ4 FY2025 → Q3 FY2026
Bear · 2

  • Tariffs absorb most of the margin gain

    Tariffs cost roughly 110 basis points of margin in the third quarter, so plant productivity is largely paying for a cost BD does not control rather than reaching profit.

    Q3 FY2026 call

  • Payouts exceed the cash the business makes

    Buybacks and dividends over the last year came to 134% of free cash flow, so shareholder returns depend partly on the balance sheet and transaction proceeds rather than on operating cash alone.

    Filed financials

Market Position

In short: BD leads most of its markets with recurring consumables, but an FDA warning letter paused some U.S. shipments.

Bull · 2

  • Leading share in most served markets

    BD holds the top position in more than 90% of the markets it sells into, and over 90% of revenue is consumables, which keeps revenue recurring and makes displacement by a competitor slow and costly for hospitals.

    Q1 FY2026 call

  • GLP-1 device contracts keep accumulating

    BD now has roughly 100 agreements covering novel and biosimilar GLP-1 molecules in its syringes, pens and autoinjectors, and management expects the franchise to keep compounding as more molecules reach the market.

    Q3 FY2026 call
Bear · 2

  • FDA warning letter paused U.S. shipments

    BD placed ChloraPrep and PurPrep on ship hold in the U.S. after a warning letter about its El Paso plant, which stops those sales until added release testing clears and carries further cost if findings repeat.

    Q2 FY2026 call

  • Little pricing power outside new launches

    Management describes pricing as flat to slightly positive before China, so most price contribution has to come from new products rather than from raising prices on the installed base, which limits how much price can add to growth.

    Q1 FY2026 call